Save
esh.org
Closing Remarks
ESH eLearning, Faculty / Presenters, 411414
Panel discussion
ESH eLearning, Faculty / Presenters, 411413
NK CAR
ESH eLearning, Rafet Basar, 411411
Is there hope for PI3K inhibitors?
ESH eLearning, Jennifer Brown, 411410
PKC beta
ESH eLearning, James Blachly, 411409
Discussion
ESH eLearning, Faculty / Presenters, 411408
CAR-T cell immunotherapy for CLL
ESH eLearning, Tanya Siddiqi, 411407
Bispecific antibodies for CLL
ESH eLearning, Arnon Kater, 411406
Beyond venetoclax: other BH3 mimetic therapies
ESH eLearning, Matthew Davids, 411405
Panel discussion
ESH eLearning, Faculty / Presenters, 411404
Resistance to non-covalent BTK inhibitors
ESH eLearning, Jennifer Brown, 411401
Resistance to covalent BTK inhibitors
ESH eLearning, Jennifer Woyach, 411400
Panel discussion
ESH eLearning, Faculty / Presenters, 411399
What role will non-covalent BTK inhibitors play?
ESH eLearning, William Wierda, 411398
Choosing a covalent BTK inhibitor
ESH eLearning, Richard Furman, 411397
Satellite Symposium: New avenues to improving outcomes for CLL patients
ESH eLearning, Faculty / Presenters, 411396
Panel discussion
ESH eLearning, Faculty / Presenters, 411395
Defined duration vs MRD driven time-limited therapy
ESH eLearning, William Wierda, 411394
BTK - BCL-2 combinations
ESH eLearning, Carsten Niemann, 411393
Venetoclax antibody combinations
ESH eLearning, Barbara Eichhorst, 411392
Discussion
ESH eLearning, Faculty / Presenters, 411391
Preclinical rationale for combining bispecific antibodies with targeted therapy for CLL
ESH eLearning, Adrian Wiestner, 411390
Antitumor immunity in the lymphoid microenvironment
ESH eLearning, Martina Seiffert, 411387
Panel discussion
ESH eLearning, Faculty / Presenters, 411386
MRD: How do we measure it? Should NGS become the standard?
ESH eLearning, Andrew Rawstron, 411385
Genomic complexity by NGS, how does it relate to karyotype?
ESH eLearning, Pauline Robbe, 411384
Are del(17p) with concurrent TP53 mutation and isolated TP53 mutation really equivalent?
ESH eLearning, Sarka Pospisilova, 411383
Panel discussion
ESH eLearning, Faculty / Presenters, 411382
Therapy of Richter Transformation
ESH eLearning, Toby Eyre, 411381
Genomics of Richter’s; are the seeds of RS present at diagnosis?
ESH eLearning, Elias Campo, 411380
Modeling Richter’s Syndrome
ESH eLearning, Elisa Ten Hacken, 411379
Panel discussion
ESH eLearning, Faculty / Presenters, 411378
Genetic evolution of CLL under therapeutic selection
ESH eLearning, Justin Taylor, 411377
Focusing on stereotyped B cell receptors in CLL
ESH eLearning, Kostas Stamatopoulos, 411376
Mutated and unmutated IGVH CLL: two different diseases? Why do they respond differently to therapies?
ESH eLearning, Paolo Ghia, 411375
Is Low Count MBL a Precursor to CLL?
ESH eLearning, Susan Slager, 411374
Welcome words
ESH eLearning, Faculty / Presenters, 411373
Conference Book (PDF)
ESH eLearning, Faculty / Presenters, 411350
Closing Remarks
ESH eLearning, Faculty / Presenters, 411238
Panel discussion
ESH eLearning, Faculty / Presenters, 411237
Case-based lecture: Steroid-refractory GVHD
ESH eLearning, Daniel Wolff, 411236
Case-based lecture: Relapse post allo HCT
ESH eLearning, Jordi Esteve, 411235
Case-based lecture: Therapy related ALL
ESH eLearning, Caner Saygin, 411234
Interactive case: First R/R AML in fit AML
ESH eLearning, Judith Schaffrath, 411233
Conference Book (PDF)
ESH eLearning, Faculty / Presenters, 411190
Panel discussion
ESH eLearning, Faculty / Presenters, 411232
Case-based lecture: Red flags for germline predisposition
ESH eLearning, Marc Raaijmakers, 411231
Case-based lecture: Controversies around donor selection and CHIP
ESH eLearning, Michael Drazer, 411230
Case-based lecture: Clonal cytopenia of unknown significance (CCUS)
ESH eLearning, Gerwin Huls, 411229
Case-based lecture: BH3 mimetics in ALL
ESH eLearning, Kristen O’Dwyer, 411201
Discussion
ESH eLearning, Faculty / Presenters, 411227
CON
ESH eLearning, Yves Chalandon, 411226
PRO
ESH eLearning, Sabina Chiaretti, 411225
Introduction
ESH eLearning, Hervé Dombret, 411224
Discussion
ESH eLearning, Faculty / Presenters, 411223
Intensive chemo
ESH eLearning, Agnieszka Wierzbowska, 411222
VenAza as first line treatment before allo
ESH eLearning, Keith Pratz, 411221
Panel discussion
ESH eLearning, Faculty / Presenters, 411220
Case-based lecture: Novel antibody and CAR-T-Cell approaches in ALL
ESH eLearning, Lori Muffly, 411219
Case-based lecture: Is antibody targeting sufficient therapy for older adults with B-ALL?
ESH eLearning, Matthew J. Wieduwilt, 411217
Interactive case: The challenge to immune targeting of AML
ESH eLearning, Marion Subklewe, 411216
Discussion
ESH eLearning, Faculty / Presenters, 411215
Real world derived control arm vs experimental arm
ESH eLearning, Megan Othus, 411214
Discussion
ESH eLearning, Faculty / Presenters, 411212
CON
ESH eLearning, Charles Craddock, 411211
Introduction
ESH eLearning, Jordi Esteve, 411209
Panel discussion
ESH eLearning, Faculty / Presenters, 411208
Case-based lecture: Post remission treatment in MRD-negative intermediate risk AML
ESH eLearning, Adriano Venditti, 411207
Case-based lecture: Management of FL3+AML after allo HCT
ESH eLearning, Alexander Perl, 411206
Case-based Lecture: What to do with TP53-mut AML?
ESH eLearning, David Sallman, 411205
Interactive case: Relapse after VenAza
ESH eLearning, Lionel Adès, 411204
Satellite Symposium: Interactive case studies for an IDH1 mutated patient ineligible for intensive chemotherapy - From diagnosis to treatment
ESH eLearning, Faculty / Presenters, 411203
Panel discussion
ESH eLearning, Faculty / Presenters, 411202
Case-based lecture: MRD directed therapy- a new therapeutic option
ESH eLearning, Andrew Wei, 411200
Case-based lecture: Menin inhibitors
ESH eLearning, Eunice Wang, 411199
Interactive case: Frontline Blinatumumab for all in ALL?
ESH eLearning, Mark Litzow, 411198
Panel discussion
ESH eLearning, Faculty / Presenters, 411197
Case-based lecture: Mixed phenotypic acute leukemias: for example: MPAL with t(v;11q23.3); KMT2A-rearranged
ESH eLearning, Etan Orgel, 411196
Case-based lecture: Extramedullary / CNS relapse in ALL
ESH eLearning, Nicolas Boissel, 411195
Case-based lecture: Blastic plasmacytoid dendritic cell neoplasm
ESH eLearning, Andrew Lane, 411194
Interactive case: Germ-line-mutation-based AML
ESH eLearning, Marie Sébert, 411193
How do the new WHO / ICC /ELN classifications impact clinical decision making?
ESH eLearning, Richard Stone, 411192
Welcome words
ESH eLearning, Faculty / Presenters, 411191
Closing remarks
ESH eLearning, Faculty / Presenters, 405454
Panel discussion
ESH eLearning, Faculty / Presenters, 405453
Therapeutic targeting of IDH1/IDH2
ESH eLearning, Eunice Wang, 405452
Therapeutic targeting of FLT3
ESH eLearning, Alexander Perl, 405451
Surface Antigen Targeting in AML: CD47 and Beyond
ESH eLearning, Ravi Majeti, 405450
NGS-based molecular MRD monitoring in AML
ESH eLearning, Peter VALK, 405449
Panel discussion
ESH eLearning, Faculty / Presenters, 405448
Molecular mechanisms driving secondary AML transformation
ESH eLearning, Coleman Lindsley, 405446
The biologic heterogeneity of secondary AML
ESH eLearning, Robert HASSERJIAN, 405445
Panel discussion
ESH eLearning, Faculty / Presenters, 405444
Therapeutic targeting of Menin
ESH eLearning, Eytan Stein, 405443
Therapeutic targeting of NPM1
ESH eLearning, Hannah Uckelmann, 405442
Therapeutic targeting of splicing factors
ESH eLearning, Matthew WALTER, 405441
Panel discussion
ESH eLearning, Faculty / Presenters, 405439
Functional single cell assessments in leukemia
ESH eLearning, Philipp Staber, 405438
Harnessing functional assays for precision medicine in AML
ESH eLearning, Raphael Itzykson, 405436

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings